APM
TEVA icon

Avidity Partners Management’s Teva Pharmaceuticals TEVA Stock Holding History

Avidity Partners Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78M Sell
200,000
-250,100
-56% -$8.33M 1.09% 14
2026
Q1 		$13.6M Buy
450,100
+32,800
+8% +$1.06M 2.75% 7
2025
Q4 		$13M Sell
417,300
-92,700
-18% -$2.28M 3.76% 5
2025
Q3 		$10.3M Sell
510,000
-179,500
-26% -$3.15M 2.34% 9
2025
Q2 		$11.6M Buy
689,500
+208,500
+43% +$3.36M 2.3% 14
2025
Q1 		$7.39M Buy
+481,000
New +$8.59M 1.41% 29

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Avidity Partners Management's TEVA Position: Q2 2026 in Review

Avidity Partners Management reduced its Teva Pharmaceuticals (TEVA) stake by 56% in Q2 2026, selling an estimated $8.33M and leaving 200,000 shares worth $6.78M. The position accounts for 1.09% of the portfolio, ranked #14.

Avidity Partners Management first reported a position in TEVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $13.6M in Q1 2026. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Avidity Partners Management held 200,000 shares of Teva Pharmaceuticals worth $6.78M as of Q2 2026.
  • Avidity Partners Management sold 250,100 Teva Pharmaceuticals shares in Q2 2026, an estimated $8.33M.
  • Teva Pharmaceuticals made up 1.09% of Avidity Partners Management's portfolio in Q2 2026, its #14 holding.
  • Avidity Partners Management first reported a position in Teva Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Avidity Partners Management's Teva Pharmaceuticals position peaked at $13.6M in Q1 2026.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.